BioMed Realty Trust Reports Third Quarter 2007 Financi...(lvingcredit facility to August 1 2012 an...),Health

During the third quarter, the company also entered into four new interest rate swaps that have the effect of fixing the LIBOR portions of interest rates on $535 million of its variable rate debt. Two of the interest rate swaps with an aggregate notional amount of $150 million fix LIBOR at 4.68% through August 2011. The remaining two interest rate swaps with an aggregate notional amount of $385 million fix LIBOR at 4.82% through September 2008.

As of September 30, 2007, the company's consolidated debt included fixed-rate mortgage indebtedness with an aggregate outstanding principal amount of $385.8 million, excluding $11.5 million of debt premium, and a weighted-average effective interest rate of 5.43% at quarter-end; the $250 million secured term loan; $175 million aggregate principal amount of 4.50% exchangeable senior notes due 2026; $216.8 million in outstanding borrowings under the company's $600 million unsecured revolving line of credit, with a weighted-average effective interest rate of 6.72% at quarter-end; and $389.9 million in outstanding borrowings under the company's $550 million acquisition and construction loan secured by the Center for Life Science | Boston property, with a weighted-average effective interest rate of 6.38% at quarter-end. The company's debt to total capitalization ratio was 43.1% at September 30, 2007.

"Our strong financial results for the quarter continue to strengthen our credit profile. We are pleased to celebrate another series of successful financing transactions, which were completed in a very difficult global credit market environment, and we appreciate the continued support of our lenders," commented Kent Griffin, Chief Financial Officer of BioMed Realty Trust. "We are fortunate to have a strong liquidity position, with ample capital capacity to continue to execute our busine
'/>"/>